Details of the Drug Formulation (DFM)
| General Information of DFM (ID: F19392) | |||||
|---|---|---|---|---|---|
| Name |
Roflumilast 0.5 mg tablet
|
||||
| Company |
AstraZeneca; Cardinal Health
|
||||
| Active Pharmaceutical Ingredient (API) | Roflumilast |
API Info
 click to show the detail info of this API
|
|||
| Chronic obstructive pulmonary disease | ICD-11: CA22 | Approved | |||
| Drug Inactive Ingredient (DIGs) | |||||
| DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
| E00DHW | DIG Info | Lactose monohydrate | Binding agent ... | ||
| E01UTP | DIG Info | Magnesium stearate | lubricant | ||
| Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
|---|---|---|---|---|---|---|
| Oxidoreductase (ORase) | ||||||
| DBT Name: Albendazole monooxygenase (CYP3A4) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Magnesium stearate | |||||
| Biological Activity | Protein expression downregulation (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP3A4_HUMAN | |||||
| References | |||||
|---|---|---|---|---|---|
| 1 | Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.